Millendo Therapeutics Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Millendo Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MLND, but not buy additional shares or sell existing shares.
View analyst ratings for Millendo Therapeutics or view top-rated stocks.

Wall Street analysts have given Millendo Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Millendo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Millendo Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 506,400 shares, an increase of 62.5% from the March 15th total of 311,600 shares. Based on an average trading volume of 870,700 shares, the days-to-cover ratio is currently 0.6 days.
View Millendo Therapeutics' Short Interest.

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Millendo Therapeutics.

Millendo Therapeutics, Inc. (NASDAQ:MLND) issued its quarterly earnings data on Sunday, March, 28th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.05.
View Millendo Therapeutics' earnings history.

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MLND stock has decreased by 85.0% and is now trading at $0.99.
View which stocks have been most impacted by COVID-19.

6 brokers have issued 12-month price targets for Millendo Therapeutics' stock. Their forecasts range from $2.00 to $6.00. On average, they expect Millendo Therapeutics' share price to reach $3.80 in the next twelve months. This suggests a possible upside of 283.8% from the stock's current price.
View analysts' price targets for Millendo Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Millendo Therapeutics include Acerus Pharmaceuticals (ASPCF), Predictive Technology Group (PRED), Acasti Pharma (ACST), Chembio Diagnostics (CEMI), Diffusion Pharmaceuticals (DFFN), Cellectar Biosciences (CLRB), Entasis Therapeutics (ETTX), CohBar (CWBR), Synthetic Biologics (SYN), Vaccinex (VCNX), Edesa Biotech (EDSA), Purple Biotech (PPBT), CannTrust (CNTTF), Monopar Therapeutics (MNPR) and Daré Bioscience (DARE).
View all of MLND's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bionano Genomics (BNGO), DURECT (DRRX), Geron (GERN) and Heat Biologics (HTBX).

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MLND stock can currently be purchased for approximately $0.99.

Millendo Therapeutics has a market capitalization of $18.85 million. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis.

Millendo Therapeutics employs 12 workers across the globe.

The official website for Millendo Therapeutics is www.millendo.com.

Millendo Therapeutics is headquartered at 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104.

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]